Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

Mesoblast LimitedTrade
Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Schwab US Dividend Equity ETF — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Schwab US Dividend Equity ETF trades at $34.29. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

MESOSCHD
Market Cap
$2.21B
Sector
TechnologyBroad Market / Factor
52-Week High
$20.96$34.27
52-Week Low
$12.88$26.44
Enterprise Value
$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.

Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.

Schwab US Dividend Equity ETF

SCHD trades at $34.26, showing modest daily gains of 0.2% with strong bullish technical signals from moving averages. The ETF maintains its position as a core dividend equity holding, though key valuation metrics remain unavailable in current data. Recent institutional activity shows Barry Investment Advisors increased their position by 29.9% during Q2 2026, indicating continued institutional confidence in the fund's strategy.

SCHD faces competition from alternative income ETFs while benefiting from the current market rotation toward value strategies. The fund's 2% yield and dividend-focused approach appeal to retirement investors, though tax efficiency considerations remain crucial for optimal positioning. Market sentiment suggests SCHD serves as a defensive holding in volatile environments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

Read more on SCHD